Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Roivant Sciences Ltd.ROIV · Entity 3185 | Director | September 16, 2026 | September 18, 2026 |
| Sio Gene Therapies Inc.AXON · Entity 130622 | Director | June 06, 2018 | June 14, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Roivant Sciences Ltd.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 123,680 |
Reported balance
After 2026-09-16 transaction · row 1
1 source rowRow 1 · 2026-09-16 · Grant · Acquired 5,054 · Balance 123,680 F1: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.57 · Expires 2036-09-15 | Direct | 10,531 |
Reported balance
After 2026-09-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-16 · Grant · Acquired 10,531 · Balance 10,531 F2: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.
F2: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.
Sio Gene Therapies Inc.
Report date June 06, 2018 · Filed June 14, 2018
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2026 Filed Sep 18, 2026 23:06 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 10,531 | $0.00 Strike: $39.57 | $0.00 |
DisclosureSEC source: 0001635088-26-000099 · wk-form4_1789772800.xml · derivative · entry 2 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,531 Underlying: Common Shares · 10,531 shares Expires 2036-09-15 F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 23:06 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 5,054 | $0.00 | $0.00 |
DisclosureSEC source: 0001635088-26-000099 · wk-form4_1789772800.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,680 F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 22:42 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 2,378 | $40.94 | $97,355.32 |
DisclosureSEC source: 0001635088-26-000092 · wk-form4_1789425749.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,626 F1 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document |
| July 17, 2026 Filed Jul 22, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 775 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-029191 · form4.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,004 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| April 17, 2026 Filed Apr 22, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 95 | $29.83 | $2,833.85 |
DisclosureSEC source: 0001140361-26-015985 · form4.xml · nonDerivative · entry 2 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,229 F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document |
| April 17, 2026 Filed Apr 22, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 896 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-015985 · form4.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,324 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 124 | $22.98 | $2,849.52 |
DisclosureSEC source: 0001140361-26-002086 · form4.xml · nonDerivative · entry 2 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,428 F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 1,164 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-002086 · form4.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,552 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| October 20, 2025 Filed Oct 23, 2025 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 281 | $17.74 | $4,984.94 |
DisclosureSEC source: 0001140361-25-038995 · form4.xml · nonDerivative · entry 2 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,388 F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document |
| October 20, 2025 Filed Oct 23, 2025 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 1,507 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-038995 · form4.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,669 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| September 10, 2025 Filed Sep 13, 2025 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 33,726 | $0.00 Strike: $13.77 | $0.00 |
DisclosureSEC source: 0001140361-25-034931 · form4.xml · derivative · entry 3 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,726 Underlying: Common Shares · 33,726 shares Expires 2035-09-09 F3 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date. Read SEC document |
| September 10, 2025 Filed Sep 13, 2025 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 2,043 | $13.77 | $28,132.11 |
DisclosureSEC source: 0001140361-25-034931 · form4.xml · nonDerivative · entry 2 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,162 F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document |
| September 10, 2025 Filed Sep 13, 2025 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 14,524 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-034931 · form4.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,205 F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date. F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date. Read SEC document |
| April 17, 2025 Filed Apr 22, 2025 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 64 | $10.15 | $649.60 |
DisclosureSEC source: 0001140361-25-014800 · form4.xml · nonDerivative · entry 2 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,500 F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document |
| April 17, 2025 Filed Apr 22, 2025 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 2,635 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-014800 · form4.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,564 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| April 17, 2025 Filed Jul 22, 2025 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 115 | $11.65 | $1,339.75 |
DisclosureSEC source: 0001140361-25-026649 · form4.xml · nonDerivative · entry 2 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,681 F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document |
| April 17, 2025 Filed Jul 22, 2025 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 2,296 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-026649 · form4.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,796 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| January 23, 2025 Filed Jan 28, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 313 | $11.21 | $3,508.73 |
DisclosureSEC source: 0001140361-25-002100 · form4.xml · nonDerivative · entry 2 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,929 F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document |
| January 23, 2025 Filed Jan 28, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 2,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-002100 · form4.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,242 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| October 21, 2024 Filed Oct 24, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 2,303 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-044059 · form4.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,856 F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| September 12, 2024 Filed Sep 17, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 3,487 | $12.12 | $42,262.44 |
DisclosureSEC source: 0001140361-24-041234 · form4.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,553 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| September 10, 2024 Filed Sep 13, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 27,894 | $0.00 Strike: $12.19 | $0.00 |
DisclosureSEC source: 0001140361-24-040985 · form4.xml · derivative · entry 2 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,894 Underlying: Common Shares · 27,894 shares Expires 2034-09-09 F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date. Read SEC document |
| September 10, 2024 Filed Sep 13, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 16,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-040985 · form4.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,040 F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date. F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date. Read SEC document |
| July 23, 2024 Filed Jul 26, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 215 | $11.01 | $2,367.15 |
DisclosureSEC source: 0001140361-24-034281 · form4.xml · nonDerivative · entry 2 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,634 F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document |
| July 23, 2024 Filed Jul 26, 2024 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 2,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-034281 · form4.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,849 F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| April 24, 2024 Filed Apr 27, 2024 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 54 | $10.90 | $588.60 |
DisclosureSEC source: 0001140361-24-022620 · form4.xml · nonDerivative · entry 2 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,409 F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares. Read SEC document |
| April 24, 2024 Filed Apr 27, 2024 01:01 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 2,121 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-022620 · form4.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,463 F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| January 19, 2024 Filed Jan 24, 2024 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 3,366 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-003551 · form4.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,342 F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| October 16, 2023 Filed Oct 19, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 2,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-048776 · form4.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,976 F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| September 18, 2023 Filed Sep 21, 2023 01:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | OtherCommon Shares | 8,703 | $11.17 | $97,212.51 |
DisclosureSEC source: 0001140361-23-044652 · form4.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,707 F1 · shares: Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4 Read SEC document |
| September 12, 2023 Filed Sep 15, 2023 01:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 26,595 | $0.00 Strike: $11.22 | $0.00 |
DisclosureSEC source: 0001140361-23-044042 · form4.xml · derivative · entry 2 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,595 Underlying: Common Shares · 26,595 shares Expires 2033-09-11 F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date. Read SEC document |
| September 12, 2023 Filed Sep 15, 2023 01:31 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 17,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-044042 · form4.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,410 F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date. F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date. Read SEC document |
| July 03, 2023 Filed Jul 7, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 1,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-033545 · form4.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,585 F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| April 03, 2023 Filed Apr 6, 2023 01:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 1,942 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-016867 · form4.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,113 F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 02:30 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 2,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-000729 · form4.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,171 F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 21:58 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 2,796 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-039661 · form4.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,161 F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
| September 15, 2022 Filed Sep 20, 2022 01:53 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantStock Option (Right to Buy) · Derivative | 71,850 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001140361-22-033877 · form4.xml · derivative · entry 2 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,850 Underlying: Common Shares · 71,850 shares Expires 2032-09-14 F2 · derivative.exercise_date: Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 15, 2023, subject generally to the reporting person's continuous service through such date. Read SEC document |
| September 15, 2022 Filed Sep 20, 2022 01:53 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 52,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-033877 · form4.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,365 F1 · shares: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 15, 2023, subject generally to the reporting person's continuous service through such date. F1 · price: Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 15, 2023, subject generally to the reporting person's continuous service through such date. Read SEC document |
| July 20, 2022 Filed Jul 25, 2022 10:05 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | GrantCommon Shares | 3,223 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-026614 · doc4.xml · nonDerivative · entry 1 Oren Ilan · CIK 0001643073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,223 F1 · shares: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. F1 · price: Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.